TrialBMC neurology2021

Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial.

R Matthew Hutchison et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.